Effects of zonisamide on neurotransmitter release associated with inositol triphosphate receptors
- PMID: 19429061
- DOI: 10.1016/j.neulet.2009.02.065
Effects of zonisamide on neurotransmitter release associated with inositol triphosphate receptors
Abstract
To clarify the antiepileptic mechanisms of zonisamide (ZNS), we determined the interaction between ZNS and inositol-1,4,5-triphosphate receptor (IP3R) on exocytosis of GABA and glutamate in rat frontal cortex using microdialysis. ZNS increased basal GABA release, but not glutamate, concentration-dependently, and reduced concentration-dependently K(+)-evoked GABA and glutamate releases. Inhibition and activation of IP3R reduced and enhanced basal and K(+)-evoked GABA releases, respectively. The K(+)-evoked glutamate release was reduced and enhanced by IP3R antagonist and agonist, respectively, whereas basal glutamate release was increased by IP3R agonist but not affected by IP3R antagonist. Under extracellular Ca(2+) depletion, IP3R agonist increased basal GABA and glutamate releases. The latter effects of IP3R agonist were weakly enhanced by ZNS, but such stimulatory action of ZNS was abolished by extracellular Ca(2+) depletion. In contrast, ZNS inhibited the stimulatory effect of IP3R agonist on K(+)-evoked release. The stimulatory effect of IP3R agonist on basal release was regulated by N-type voltage-sensitive Ca(2+) channel (VSCC) rather than P- and L-type VSCCs, whereas the stimulatory effect of IP3R agonist on K(+)-evoked release was regulated by P- and L-type VSCCs rather than N-type VSCC. These results suggest that ZNS-activated N-type VSCC enhances IP3R-associated neurotransmitter release during resting stage, whereas ZNS-induced suppression of P- and L-type VSCCs possibly attenuates IP3R-associated neurotransmitter release during neuronal hyperexcitability. Therefore, the combination of both of these two actions of ZNS on IP3R-associated neurotransmitter release mechanism seems to be involved, at least in part, in the mechanisms of antiepileptic and neuroprotective actions of ZNS.
Similar articles
-
Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors.Epilepsy Res. 2005 Dec;67(3):153-62. doi: 10.1016/j.eplepsyres.2005.10.001. Epub 2005 Nov 10. Epilepsy Res. 2005. PMID: 16289509
-
Carbamazepine prevents breakdown of neurotransmitter release induced by hyperactivation of ryanodine receptor.Neuropharmacology. 2007 Jun;52(7):1538-46. doi: 10.1016/j.neuropharm.2007.02.009. Epub 2007 Mar 12. Neuropharmacology. 2007. PMID: 17445842
-
Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.Neuropharmacology. 2009 Sep;57(3):322-31. doi: 10.1016/j.neuropharm.2009.05.005. Epub 2009 May 29. Neuropharmacology. 2009. PMID: 19482038
-
Exocytosis mechanism as a new targeting site for mechanisms of action of antiepileptic drugs.Life Sci. 2002 Dec 20;72(4-5):465-73. doi: 10.1016/s0024-3205(02)02283-x. Life Sci. 2002. PMID: 12467887 Review.
-
Zonisamide: a new antiepileptic drug.Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. Pol J Pharmacol. 2003. PMID: 14704463 Review.
Cited by
-
Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives.Molecules. 2021 Oct 22;26(21):6380. doi: 10.3390/molecules26216380. Molecules. 2021. PMID: 34770789 Free PMC article. Review.
-
Transcriptomic analysis in a Drosophila model identifies previously implicated and novel pathways in the therapeutic mechanism in neuropsychiatric disorders.Front Neurosci. 2011 Mar 31;5:161. doi: 10.3389/fnins.2011.00161. eCollection 2011. Front Neurosci. 2011. PMID: 21503142 Free PMC article.
-
Pathogenesis and pathophysiology of autosomal dominant sleep-related hypermotor epilepsy with S284L-mutant α4 subunit of nicotinic ACh receptor.Br J Pharmacol. 2020 May;177(9):2143-2162. doi: 10.1111/bph.14974. Epub 2020 Feb 15. Br J Pharmacol. 2020. PMID: 31901135 Free PMC article.
-
Placebo-controlled trial of zonisamide for the treatment of alcohol dependence.J Clin Psychopharmacol. 2010 Jun;30(3):318-22. doi: 10.1097/JCP.0b013e3181db38bb. J Clin Psychopharmacol. 2010. PMID: 20473070 Free PMC article. Clinical Trial.
-
Effect of 4-Fluoro-N-(4-Sulfamoylbenzyl) Benzene Sulfonamide on Acquisition and Expression of Nicotine-Induced Behavioral Sensitization and Striatal Adenosine Levels.Drug Des Devel Ther. 2020 Sep 17;14:3777-3786. doi: 10.2147/DDDT.S270025. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32982182 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous